First Tracks Biotherapeutics, Inc.
Explore First Tracks Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Pros
No pros available.
Cons
No cons available.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $676.23 | 15.66 | $69.27 B | 0.56% | 10.23% | 14.32% | $821.11 / $532.6 | $295.71 |
| 3. | Alnylam Pharmaceuticals, Inc. | $321.59 | 73.48 | $42.41 B | — | 14.33% | 98.29% | $495.55 / $273.11 | $5.96 |
| 4. | Revolution Medicines, Inc. | $190.46 | — | $40.7 B | — | -57.28% | -54.06% | $193.69 / $34 | $8.28 |
| 5. | Roivant Sciences Ltd. | $36.31 | — | $34.93 B | — | -21.06% | -6.85% | $36.49 / $10.71 | $6.28 |
| 6. | Royalty Pharma plc | $57.8 | 40.22 | $33.27 B | 1.63% | 8.21% | 12.67% | $58.17 / $34.08 | $11.22 |
| 7. | Moderna, Inc. | $79.77 | — | $31.62 B | — | -29.7% | -36.73% | $85.6 / $22.28 | $21.95 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q1 2025 | |
|---|---|---|
| Sales | 0 M | 0 M |
| Operating Profit | -52.81 M | -51.28 M |
| Net Profit | -50.48 M | -47.2 M |
| EPS in Rs | -1.45 | -1.36 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | |
|---|---|---|
| Sales | 0 M | 0 M |
| Operating Profit | -181.1 M | -118.46 M |
| Net Profit | -163.71 M | -106.15 M |
| EPS in Rs | — | -3.05 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | |
|---|---|---|
| Total Assets | 441.89 M | 444.11 M |
| Total Liabilities | 50.3 M | 34.26 M |
| Equity | 391.6 M | 409.85 M |
| Current Assets | 389.93 M | 398.56 M |
| Current Liabilities | 36.18 M | 18.22 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | |
|---|---|---|
| Operating CF | -125.81 M | -93 M |
| Investing CF | 95.4 M | 144.75 M |
| Financing CF | 117.52 M | -87.09 M |
| Free CF | -126.16 M | -93.81 M |
| Capex | -0.36 M | -0.81 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | |
|---|---|---|
| Revenue Growth % | — | — |
| Earnings Growth % | -54.22% | — |
| Profit Margin % | — | — |
| Operating Margin % | — | — |
| Gross Margin % | — | — |
| EBITDA Margin % | — | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.
Frequently Asked Questions — First Tracks Biotherapeutics, Inc.
Will First Tracks Biotherapeutics, Inc. stock hit $21 in 2026?
First Tracks Biotherapeutics, Inc. (TRAX) is currently trading at $17.42, with a 52-week range of $14.72 to $26.8. Reaching the $21 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Wall Street analysts currently have a consensus price target of $38.12 for First Tracks Biotherapeutics, Inc., with a Strong_buy rating, and the most bullish analysts see the stock reaching as high as $54.0. Whether First Tracks Biotherapeutics, Inc. can reach $21 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Short-term price predictions carry significant uncertainty — stock prices can be influenced by factors ranging from quarterly earnings surprises to global macroeconomic events. Use the TRAX Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is First Tracks Biotherapeutics, Inc. stock worth buying at $17.42?
Whether First Tracks Biotherapeutics, Inc. (TRAX) is worth buying at $17.42 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.
Profitability & efficiency:
Financial health: Review the balance sheet section on StockSifting for the latest debt levels, cash reserves, and liquidity ratios.
Analyst view: The Wall Street consensus recommendation for TRAX is currently Strong_buy, with a mean price target of $38.12 based on 8 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for First Tracks Biotherapeutics, Inc. (TRAX) in 2026?
As of 2026, Wall Street analysts have set a consensus (mean) price target of $38.12 for First Tracks Biotherapeutics, Inc. (TRAX), aggregated from 8 analyst ratings. The overall analyst recommendation is Strong_buy.
The price target range spans from $30.0 on the bearish end to $54.0 on the most optimistic projection, with a median target of $35.0. This wide range reflects differing views on First Tracks Biotherapeutics, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.
It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the TRAX analysis page on StockSifting.
What will First Tracks Biotherapeutics, Inc. stock be worth in 2029?
Projecting First Tracks Biotherapeutics, Inc. (TRAX)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.
In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.
You can model different scenarios — conservative, base, and bull case — using the TRAX Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.